吉西他滨联合卡培他滨治疗蒽环类耐药性晚期乳腺癌临床效果和安全性分析.docVIP

吉西他滨联合卡培他滨治疗蒽环类耐药性晚期乳腺癌临床效果和安全性分析 　　[摘要]目的 探讨吉西他滨联合卡培他滨治疗蒽环类耐药性晚期乳腺癌的临床效果和安全性。方法 将2013年6月～2015年11月于我院确诊为蒽环类耐药性晚期乳腺癌的79例患者纳入研究并随机分组，对照组39例患者采用多西紫杉醇联合卡培他滨治疗，观察组40例则采用吉西他滨联合卡培他滨。治疗2周期后比较两组的临床疗效，Ⅲ、Ⅳ度消化道不适及骨髓抑制等毒副作用发生情况。结果 观察组总缓解率为47.50%，明显高于对照?M（25.64%），差异有统计学意义（P0.05）；观察组Ⅲ、Ⅳ度消化道不适发生率为17.50%，骨髓抑制率为22.50%，低于对照组（38.46%、43.59%）（P0.05），观察组消化道不适毒及骨髓抑制总发生率均低于对照组，差异均有统计学意义（P0.05）。结论 吉西他滨联合卡培他滨治疗蒽环类耐药性晚期乳腺癌效果显著，且不良反应小，值得推广。 　　[关键词]吉西他滨；卡培他滨；耐药性；晚期乳腺癌；疗效；安全性 　　[中图分类号] R737.9 [文献标识码] A [文章编号] 1674-4721（2016）11（c）-0094-04 　　[Abstract]Objective To explore the clinical efficacy and safety of Gemcitabine combining with Capecitabine in the treatment of advanced breast cancer with Anthracycline resistance.Methods From June 2013 to November 2015，79 patients definitely diagnosed as advanced breast cancer with Anthracycline-resistant in our hospital were enrolled in the study and randomly assigned to control group （n=39） and observation group （n=40）.In the control group，patients were treated with Docetaxel and Capecitabine，while in the observation group，Gemcitabine combined with Capecitabine was used.After 2 cycles of treatment，the difference of clinical curative effect，the digestive tract discomfort in Ⅲ and Ⅳ degrees and the occurrence of side effects such as bone marrow suppression were compared between the two groups.Results The total remission rate in the observation group was 47.50%，was higher than that in the control group （25.64%），the difference was statistically significant （P0.05）；the incidence of digestive tract discomfort in degree Ⅲ and Ⅳ and myelosuppression in the observation group was 17.50% and 22.50%，was lower than those of the control group （38.46%，43.59%），and the overall incidence of the digestive tract discomfort in degree Ⅲ and Ⅳ and myelosuppression between the two groups had statistically significant difference （P0.05）.Conclusion Combination of Gemcitabine and Capecitabine in the treatment of advanced breast cancer with Anthracycline-resistant has a great effe